United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan
Rhea-AI Filing Summary
United Therapeutics chairperson and CEO Martine A. Rothblatt, indirectly through family trusts, exercised 9,500 stock options at $135.4200 per share on August 4, 2026 and received an equal number of common shares.
On the same date those 9,500 shares were sold in multiple tranches at reported weighted average prices such as $512.4859, $516.5935 and $517.4960 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
The plan continues until the earlier of exercising up to 1,734,410 stock options expiring March 15, 2027 or December 31, 2026; 208,410 stock options remain held indirectly in a family trust, plus 40,513 shares held directly and 166 shares held indirectly by a spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.63M approx. pre-tax spread)
Exercise and Sale
16 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.91M)
Approx. gross sale proceeds
$4.91M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.63M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 178 | $512.4859 | $91K |
| Sale | Common Stock F1, F4, F2 | 182 | $513.3945 | $93K |
| Sale | Common Stock F1, F5, F2 | 675 | $514.4272 | $347K |
| Sale | Common Stock F1, F6, F2 | 605 | $515.4991 | $312K |
| Sale | Common Stock F1, F7, F2 | 2,456 | $516.5935 | $1.27M |
| Sale | Common Stock F1, F8, F2 | 3,142 | $517.496 | $1.63M |
| Sale | Common Stock F1, F9, F2 | 1,446 | $518.3964 | $750K |
| Sale | Common Stock F1, F10, F2 | 517 | $519.4994 | $269K |
| Sale | Common Stock F1, F11, F2 | 299 | $520.4884 | $156K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F12 | -- | -- | -- |
| holding | Common Stock F13 | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 208,410 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $519.05 to $520.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $520.16 to $520.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F13. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F14. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $511.96 to $512.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $512.98 to $513.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $513.98 to $514.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $514.99 to $515.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $516.04 to $517.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $517.04 to $518.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $518.04 to $519.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Option exercise price: $135.4200 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 shares
Stock options exercised indirectly through a family trust on 2026-08-04 into common stock
Option exercise price
$135.4200 per share
Exercise price for the 9,500 stock options converted into United Therapeutics common stock
Shares sold
9,500 shares
Total United Therapeutics common shares sold indirectly through family trusts on 2026-08-04
Representative sale price
$516.5935 per share
Weighted average price for a 2,456-share sale tranche of common stock on 2026-08-04
Options remaining in trust
208,410 stock options
Indirectly held stock options reported following the 9,500-option exercise
Direct common shares held
40,513 shares
United Therapeutics common stock held directly by Martine A. Rothblatt as of 2026-08-04
Indirect spouse holdings
166 shares
Common shares held indirectly through the reporting person's spouse as of 2026-08-04
10b5-1 plan option cap
1,734,410 stock options
Maximum stock options to be exercised under the Rule 10b5-1 plan before December 31, 2026
Key Terms
pre-arranged 10b5-1 trading plan, weighted average price, stock options, family trusts
4 terms
pre-arranged 10b5-1 trading plan regulatory
"pursuant to a pre-arranged 10b5-1 trading plan adopted by the"
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person's spouse"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did United Therapeutics (UTHR) CEO Martine Rothblatt report in this Form 4?
Rothblatt reported indirectly exercising 9,500 stock options at $135.4200 per share and receiving 9,500 United Therapeutics common shares, then selling those 9,500 shares in multiple transactions through family trusts on August 4, 2026 under a Rule 10b5-1 plan.
What stock options in United Therapeutics (UTHR) did Rothblatt exercise?
Rothblatt indirectly exercised 9,500 United Therapeutics stock options at an exercise price of $135.4200 per share, converting them into 9,500 common shares. These options are part of a larger pool of up to 1,734,410 options covered by a trading plan.
Were the United Therapeutics (UTHR) insider transactions made under a Rule 10b5-1 plan?
Yes. The option exercise and resulting share sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of exercising up to 1,734,410 options or December 31, 2026.
What United Therapeutics (UTHR) holdings does Rothblatt report after these trades?
After the reported transactions, Rothblatt reports 208,410 stock options held indirectly in a family trust, 40,513 United Therapeutics shares held directly, and 166 shares held indirectly by a spouse, along with additional share positions held through various family trusts with shared investment power.